SCAND1 (SCAN domain containing 1) is a transcriptional co-regulator that functions as a SCAN domain-only protein capable of hetero-oligomerizing with SCAN-zinc finger transcription factors like MZF1 to access DNA and mediate transcriptional co-repression 1. At the molecular level, SCAND1 heterodimerizes with zinc finger proteins through its SCAN domain 2 and coordinately binds chr20 with heterochromatin protein HP1γ 3. Clinically, SCAND1 exhibits tumor-suppressive properties, particularly in prostate cancer where it reverses epithelial-to-mesenchymal transition (EMT) by suppressing EMT driver genes (ZEB1/2, CTNNB1, TGFBRs) and inhibiting MAP3K-MEK-ERK signaling, thereby reducing proliferation, migration, and lymph node metastasis 3. As a stress-inducible factor, SCAND1 suppresses excessive heat shock responses by co-repressing HSP90 gene expression, functioning as a negative feedback regulator of cellular stress 1. High SCAND1 expression correlates with improved prognoses in pancreatic and head/neck cancers, and potentially in lung adenocarcinoma 1. Additionally, SCAND1 was identified as a component of prognostic models for non-small cell lung cancer 4 and breast cancer 5, indicating its value as a prognostic biomarker. A genetic variant near SCAND1 shows association with plasma HDL cholesterol levels 6.